A pharmacoepigenetic biomarker tool for prediction of response and tolerance to treatment in type 2 diabetes
| Reference number | |
| Coordinator | Lunds universitet - Lunds universitet (IKVM) Inst f kliniska vetenskaper |
| Funding from Vinnova | SEK 4 498 554 |
| Project duration | February 2026 - January 2029 |
| Status | Ongoing |
| Venture | European partnership for Personalised Medicine |
| Call | International collaboration in pharmacogenomics in personalised medicine |
Purpose and goal
It is crucial that people with Type 2 Diabetes (T2D) receive optimal therapy already at diagnosis to optimize metabolic control. Response to therapy is heterogenous. ~30% of people with T2D do not respond to firstline therapy, metformin, and may benefit from earlier treatment with other drugs. No biomarkers have been approved for predicting response to T2D therapies. EPIPREDIA aims to will tackle this unmet need by developing pharmacoepigenetic biomarkers predicting response to treatment in T2D.
Expected effects and result
We expect to identify novel blood-based epigenetic biomarkers that predict response to pharmacotherapy and complications in people with T2D. Our results will be used to develop new strategies for precision medicine in T2D. It will help patients receive optimal therapy, improving cardiovascular protection, reducing mortality and cost for society.
Planned approach and implementation
We will use prospective cohorts and analyse epigenetics in blood, to discover and validate blood-based biomarkers predicting glycaemic response and tolerance to T2D drugs in newly diagnosed patients with T2D. Next, we plan to develop a clinically useful product for personalised T2D medicine. It will help patients receive optimal therapy, improving cardiovascular protection, reducing mortality and cost for society.